Hubbry Logo
Baxter InternationalBaxter InternationalMain
Open search
Baxter International
Community hub
Baxter International
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Baxter International
Baxter International
Baxter International
View on Wikipedia
from Wikipedia

Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.[2]

Key Information

The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion (+2% vs 2022), across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.

Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients.

Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services".

Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology.

History

[edit]

Baxter International was founded in 1931 by Donald Baxter, a Los Angeles-based medical doctor, as a manufacturer and distributor of intravenous therapy solutions.[3] Seeing a need for products closer to the Midwest, the company opened a manufacturing plant in Glenview, Illinois, in 1933.[3] Baxter's interest was bought out in 1935 by Ralph Falk, who established a research and development function.[4] In 1939 the company developed a vacuum-type collection container, extending the shelf life of blood from hours to weeks.[4] In 1954, the company expanded operations outside of the United States by opening an office in Belgium.[5] In 1956 Baxter International introduced the first functioning artificial kidney, and in 1971 became a member of the Fortune 500.

In 1971, Baxter built a major manufacturing plant in Ashdod, Israel. As a result, the company was placed on the Arab League boycott list in the early 1980s.[6]

Throughout the 1980s and 1990s, the company expanded to deliver a wider variety of products and services (including vaccines and a greater variety of blood products) through acquisitions of various companies. Sales and production facilities also expanded throughout the world.[3]

In 1982, Baxter acquired Medcom, Inc., a New York-based firm founded by Richard Fuisz and his brother, that had large markets in the United States and Saudi Arabia.[7][8][9] Baxter chief executive Vernon Loucks fired Fuisz who then brought anti-boycott charges against Baxter to the U.S. Commerce Department Office of Anti-Boycott Compliance (OAC). Fuisz alleged that Baxter had sold their profitable Ashdod facility to Teva Pharmaceutical Industries in 1988[10] while simultaneously negotiating the construction of a similar plant in Syria in partnership with the Syrian military in order to be removed from the Arab League blacklist in 1989.[6][11][12] In 1993 Baxter pleaded guilty to a felony in relation to an anti-boycott law in the United States.[10][13]

On July 15, 1985, American Hospital Supply Corporation CEO Karl D. Bays and Baxter's then-CEO Vernon R. Loucks Jr. signed an agreement that merged two of the United States' "largest producers of medical supplies".[14] This was a "one-Baxter approach" in which the company provided "70% to 80% of what a hospital needed."[15]

In 1991, Baxter's home infusion subsidiary, Caremark International, "was accused by the government of paying doctors to steer patients to its intravenous drug service"[16] In 1992 Caremark spun off from Baxter International.[16] Caremark was fined $160 million for the "four-year-long federal mail-fraud and kickback" scheme in which the "home-infusion business unit made weekly payments to scores of doctors that averaged about $75 per patient for referring those patients to its services. Some doctors earned as much as $80,000 a year from the kickbacks, according to government documents."[16]

In 1996, the company entered into a four-way, $640 million settlement with haemophiliacs 1999 in relation to blood clotting concentrates that were infected with HIV.[17] Under pressure from shareholders due to poor performance and an unsuccessful merger, Loucks was forced to resign.[13]: 115 

Baxter acquired medical device firm Baxa on November 10, 2011.[18] In 2011, Hikma Pharmaceuticals PLC completed the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).[19][20]

In July 2013, EU antitrust regulators approved Baxter's bid for Sweden's Gambro.[21]

In March 2014, Baxter announced plans to create two independent global healthcare companies—one focused on developing and marketing bio-pharmaceuticals and the other on medical products. The medical products company retained the name Baxter International Inc. and the bio-pharmaceuticals company is named Baxalta and spun-off as a new public company that showed on trading boards as of July 1, 2015.[22]

In July 2014, Baxter announced that it was exiting the vaccines business—divesting its commercial vaccine portfolio to Pfizer (with the sale expected to close by the end of the year) and exploring options for its vaccines R&D program, including influenza.[23] In October 2015, José E. Almeida was named chairman and chief executive officer.[24] In January 2016 Shire PLC agreed to acquire Baxalta for $32 billion.[25]

In December 2016, Baxter announced it would acquire Claris Lifesciences injectables subsidiary, Claris Injectables, for $625 million.[26]

In December 2019, the company announced it would acquire Seprafilm from Sanofi for $350 million.[27][28]

In September 2021, Baxter announced it would acquire Hill-rom for $12.4 billion.[29] The acquisition was completed in December 2021 for $12.5 billion.[30] [31]

In May 2023, Baxter announced it was selling its biopharma solutions business, which offers drugmakers support in the form of products like injectable delivery systems and services that include regulatory resources, help with drug formulation and development, and packaging capabilities, to private equity firms Warburg Pincus and Advent International for $4.25 billion in cash.[32][33]

In August 2024, Baxter agreed to divest its kidney care business unit, Vantive, to private equity firm Carlyle Group for $3.8 billion.[34]

In September 2024, Hurricane Helene caused significant flooding in North Carolina, affecting a Baxter International facility in Marion. This facility produces approximately 60% of the intravenous (IV) fluids used in the United States. The disruption led to nationwide IV fluid shortages, prompting hospitals to ration supplies and implement strategies to conserve fluids. This also prompted questions from medical professionals about why such a large portion of the country's IV manufacturing capacity is tied to a single facility. As of November 7, 2024, the facility resumed producing some IV fluids. However, with the onset of flu season, hospitals continued to prioritize conservation efforts.[35]

Environmental activities

[edit]

In 1997, a report produced by the company indicated that changes made to reduce environmental impacts generated savings that exceeded their cost, producing a net profit. Reporting was company-wide, with a variety of aggregation and reporting, including on the company's internet and intranet sites.[36] The company was an early joiner in the "green and greedy" movement, which aims to lessen the environmental impacts of manufacturing its products while saving the company money.[37] In 2009 the company announced it had reached a variety of its environmentally friendly goals, and that it would continue to try to reduce waste, emissions, energy use and environmental incidents over the coming years.[38]

Structure

[edit]
Baxter International by businessline [39][40]
Name Focus 2013 sales (in billions) Percentage of total sales
BioScience Haemophilia therapy; antibody therapy; critical care therapy; pulmonology therapy; biosurgery products; vaccines $6.4 43%
Medical Products IV solutions, premixed drugs, infusion pumps and administration sets; parenteral nutrition products; anesthesia; drug formulation and pharma partnering; peritoneal dialysis products; hemodialysis products; continuous renal replacement therapy $10.3 57%

The company had 2014 sales of $16.7 billion, across two businesses: BioScience (2013 sales - $6.6 billion) and Medical Products ($8.7 billion).[41] Sales in 2013 were 42% in the United States, 30% in Europe, 16% in Asia Pacific, 12% in Latin America and Canada. In 2011, Baxter had approximately 61,500 employees. The breakdown of regional employees in 2013 was 36% in the United States; 34% in Europe; 16% in Asia Pacific; 14% in Latin America and Canada. In 2013, Baxter International spent more than $1.2 billion on research and development.[42] As of December 31, 2016, the company had approximately 48,000 employees.[43]

Corporate governance

[edit]

In 1953 William Graham became the company's CEO. Vernon Loucks became president and CEO in 1980. Loucks was forced to resign by shareholders.[13][44]

In January, as Baxter International Inc.'s Vernon Loucks relinquished his CEO duties after 18 years, directors handed him a special stock-option grant of 950,000 shares "for the specific purposes of motivating" him "to implement a smooth transition of his responsibilities." If Mr. Loucks sells all the 400,000 shares he can exercise at year end and Baxter's stock price remains at its current level, he will make more than $4 million.

— The Wall Street Journal, April 29, 1999

During the tenure of Vernon Loucks, who was Baxter's CEO from 1980 to 1998 and chairman from 1987 to 1999, company sales "more than quadrupled to $5.7 billion while its workforce rose from 30,000 to 42,000." During that time, Loucks hired and groomed staff who went on to become CEOs elsewhere. Baxter alumni groomed by Loucks included Terry Mulligan of MedAssets, Lance Piccolo at Caremark, Mike Mussallem of Edwards Lifesciences Corp and CEOs of Boston Scientific Corp. and Cardinal Health.[15]

Loucks was succeeded by Harry Kraemer, who was succeeded by Robert Parkinson, who took the CEO position in 2004.[3]

H1N1 vaccine

[edit]

In July 2009, Baxter International announced completion of the first commercial vaccine for the H1N1 ("swine flu") influenza.[45] The company has been one of several working with the World Health Organization and United States Centers for Disease Control and Prevention on the vaccine, and uses a cell-based rather than egg-based technology that allows a shorter production time.[46]

Philanthropy

[edit]

In 2008, Baxter launched Science@Work: Expanding Minds with Real-World Science, which supports teacher training and student development in healthcare and biotechnology in Chicago Public Schools.[47]: 17 

In 2013, the company was included in The Civic 50, a list of the most community-minded companies in America from The National Conference on Citizenship and Points of Light, published by Bloomberg.[48]

In 2014, roughly 6,300 Baxter employees volunteered in their communities through The Baxter International Foundation's Dollars for Doers program, addressing local concerns such as healthcare, the environment and education.[49]: 104  In 2014, Baxter and The Baxter International Foundation gave over $50 million.[50]

Baxter was included for the 13th year in Corporate Responsibility magazine's 100 Best Corporate Citizens list in 2014 for its social responsibility performance.[51]

Product defects and contamination

[edit]

In August 1975, Baxter / Travenol withdrew a clotting factor product Hemofil after the product was associated with an outbreak of hepatitis B.[52]

Baxter, unknown to the FDA, continued to use prison plasma in factor concentrate production until October 1983, despite having entered into an agreement with the FDA (11 months earlier) that they would no longer use US prison plasma, which posed a high risk of virus transmission.[53]

It was announced in quarter 1 of 1996 that Baxter had agreed to settle a lawsuit involving 200 Japanese haemophilia patients who had become infected with HIV as a result of using contaminated haemophilia products which were unheated. The Japanese courts ordered for each victim to receive $411,460 by March 29 that year.[54]

In 2010, a jury in Las Vegas, Nevada, ordered Baxter and Teva Pharmaceuticals to pay $144 million to patients who had been infected with hepatitis C after doctors wrongly reused dirty medical supplies to administer propofol to patients, although the label for propofol clearly states that it is for single-patient use only and that aseptic procedures should be used at all times.[55] Per a 2009 indemnity agreement between Teva (the manufacturer) and Baxter (acting as a distributor on behalf of Teva), the litigation and related settlements were defended and paid by Teva.[56]

In 2010, Baxter was ordered by the FDA to recall all of their Colleague infusion pumps from the market due to 87 recalls and deaths associated with the pump.[57]

2001 Althane disaster

[edit]
Main article: Baxter Althane disaster

The Baxter Althane disaster in autumn 2001 was a series of over 50 sudden deaths of kidney failure patients in Spain, Croatia, Italy, Germany, Taiwan, Colombia and the USA (mainly Nebraska and Texas). All had received hospital treatment with Althane hemodialysis equipment, a product range manufactured by Baxter International, USA.[58][59]

2008 Chinese heparin adulteration

[edit]
Main article: 2008 Chinese heparin adulteration

In 2008, the quality of blood thinning products produced by Baxter was brought into question when they were linked to 81 deaths and 785 severe allergic reactions in the United States according to the FDA.[60] Upon inspection, one of the raw ingredients used by Baxter was found to be contaminated – between 5 and 20 percent – with a substance that was similar, but not identical, to the ingredient itself. The company initiated a voluntary recall, temporarily suspended the manufacture of heparin, and launched an investigation.

The investigation into the contamination has focused on raw heparin produced by one of Baxter's subcontractors Changzhou Scientific Protein Laboratories, a China-based branch of Scientific Protein Laboratories, based in Waunakee, Wisconsin. Changzhou SPL's facilities were never subjected to inspection by US FDA officials. In addition, Changzhou SPL's products were also never certified as safe for use in pharmaceutical products by Chinese FDA officials, due to Changzhou SPL's registration as a chemical company rather than a pharmaceutical manufacturer.[61][62][63]

Upon investigation of these adverse events by the FDA, academic institutions, and the involved pharmaceutical companies, the contaminant was identified as an "over-sulfated" derivative of chondroitin sulfate, a closely related substance obtained from mammal or fish cartilage and often used as a treatment for arthritis.[64][65] Since over-sulfated chondroitin is not a naturally occurring molecule, it costs a fraction of true heparin precursor chemical, and mimics the in-vitro properties of heparin, the counterfeit was almost certainly intentional as opposed to an accidental lapse in manufacturing.[66] The raw heparin batches were found to have been cut from 2–60% with the counterfeit substance, and motivation for the adulteration was attributed to a combination of cost effectiveness and a shortage of suitable pigs in Mainland China. In mid-January 2008 Baxter voluntarily recalled some lots of multi-dose vials of Heparin in February in consultation with the FDA Baxter recalled the rest of their Heparin products.[60]

2009 Avian flu contamination

[edit]

In early 2009, samples of viral material supplied by Baxter International to a series of European laboratories were found to be contaminated with live Avian flu virus (Influenza A virus subtype H5N1).[67] Samples of the less harmful seasonal flu virus (subtype H3N2) were found to be mixed with the deadly H5N1 strain after a vaccine made from the material killed test animals in a lab in the Czech Republic. Though the serious consequences were avoided by the lab in the Czech Republic,[68] Baxter then claimed the failed controls over the distribution of the virus were 'stringent' and there was 'little chance' of the lethal virus harming humans.[69]

2009 drug cost inflation

[edit]

On July 2, 2009, Kentucky Attorney General Jack Conway announced a settlement between the state and Baxter Healthcare Corporation, a subsidiary of Baxter International, worth $2 million. The company had been inflating the cost of the intravenous drugs sold to Kentucky Medicaid, at times as much as 1300%.[70]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Baxter International

View on Grokipedia
from Grokipedia

Baxter International Inc. is an American multinational healthcare company that develops, manufactures, and markets a broad portfolio of medical products and therapies, including intravenous solutions, renal care systems, nutritional support, and surgical equipment, with a mission to save and sustain lives through innovations utilized in hospitals, clinics, and patient care settings worldwide. Founded in 1931 by physicians Donald Baxter and Ralph Smith Falk as the Don Baxter Intravenous Products Corporation in Glendale, California, the company pioneered the first commercially produced intravenous solutions, addressing critical needs for standardized parenteral nutrition and fluid therapy. Over nearly a century, Baxter has expanded through acquisitions and internal development to introduce key medical advancements, such as early blood collection and storage systems, the first commercial kidney dialysis equipment, and advanced hospital pharmacy compounding technologies, operating in over 100 countries with a workforce dedicated to solving unmet patient care challenges. The company maintains a focus on acute therapies, nutrition, and structural heart interventions, though it has encountered regulatory scrutiny, including a 2017 settlement exceeding $18 million for violations of current good manufacturing practices in pharmaceutical production. In recent years, has faced securities lawsuits alleging misrepresentations regarding the safety and performance of products like the IQ Large Volume Pump, contributing to significant stock price declines in 2025 amid ongoing investigations into and disclosure issues. Despite these challenges, reported second-quarter 2025 sales growth from continuing operations while adjusting full-year forecasts downward due to operational and external pressures.

Company Overview

Founding and Core Mission

Baxter International originated from the Don Baxter Intravenous Products Corporation, founded on June 15, 1931, by physicians Donald E. Baxter and Ralph Falk in , with initial involvement from Harry Falk. The company commenced operations as the first commercial manufacturer of sterile, pre-prepared intravenous (IV) solutions, addressing the era's reliance on hospital pharmacies mixing solutions manually—a process vulnerable to bacterial contamination and inconsistent sterility. By 1932, despite early financial losses of $12,900, it established production facilities to supply hospitals with safer alternatives for hydration and drug administration. The founding impetus derived from Dr. Baxter's clinical observations, including difficulties in delivering reliable IV therapy during his 1924 medical work in a remote Chinese village, where improvised solutions highlighted risks of and supply shortages. This experience underscored the causal link between preparation methods and patient outcomes, prompting and Falk to industrialize IV production using vacuum-sealed glass containers to ensure sterility and . Their approach prioritized empirical improvements in , reducing variability inherent in ad-hoc . From its inception, the core mission centered on advancing therapies to mitigate life-threatening complications from inadequate fluid management, embodying a commitment to evidence-based in critical care. This foundational focus on sterile delivery systems laid the groundwork for broader renal and nutritional products, consistently emphasizing patient-centric reliability over prior artisanal methods.

Current Scope and Global Presence

Baxter International Inc. specializes in medical products and therapies for use in hospitals, clinics, and other care settings, emphasizing systems, intravenous solutions, delivery, nutritional products, respiratory care, and surgical equipment. Following the sale of its BioPharma Solutions business in 2023 and the Kidney Care segment to Vantive Corporation in February 2024, the company's continuing operations are consolidated under the Medical Products and Therapies segment, which encompasses acute and supportive care solutions such as automated pumps, , and connected monitoring devices. In 2024, this segment generated worldwide sales of $10.64 billion, reflecting a 3% increase on both reported and constant currency bases from the prior year. The company maintains a global operational footprint, with products distributed in over 100 countries and international comprising $4.79 billion, or about 45% of total 2024 continuing operations . Baxter's presence spans , , , , and other regions, supported by a network of distribution centers and strategic partnerships to ensure amid geopolitical and logistical challenges. In the second quarter of 2025, from continuing operations reached $2.81 billion, up 4% reported and 1% operational year-over-year, driven by growth in core therapy areas despite headwinds. Baxter continues to prioritize in connected care technologies and personalized therapies, with ongoing investments in and across its international sites to meet demand in high-growth markets like emerging economies. The firm's global strategy emphasizes operational execution in established segments, projecting full-year sales growth of 6% to 7% on a reported basis from continuing operations.

Historical Development

Origins and Early Innovations (1931–1960)

traces its origins to 1931, when physicians Donald E. Baxter and Ralph S. Falk established the Don Intravenous Products Corporation in , as the first commercial manufacturer of pre-prepared intravenous (IV) solutions. Prior to this, hospitals compounded IV fluids on-site, often leading to risks and inconsistencies, a problem had observed during his work as a medical amid outbreaks. The company's initial products standardized saline and dextrose solutions in glass containers, improving safety and efficiency for in clinical settings. By 1933, had opened its first manufacturing facility in , to meet growing demand from Midwestern hospitals. In the 1930s, Baxter pioneered blood collection and storage technologies, introducing the Transfuso-Vac vacuum-sealed glass container around 1939, which permitted sterile blood banking for up to 21 days under —a critical advancement for before widespread refrigeration infrastructure. This innovation addressed the limitations of open-vessel methods prone to bacterial contamination. During , the company expanded production to support military needs, further refining IV and blood products. By 1941, Baxter launched the Plasma-Vac system, enabling the separation and long-term storage of plasma from , which facilitated component therapy and reduced logistical challenges in blood supply chains. In 1948, the firm introduced unbreakable plastic bags for blood storage, replacing fragile glass and minimizing breakage risks during transport. The 1950s marked Baxter's diversification into plasma-derived therapies and renal care. In 1950, a second U.S. plant opened in , dedicated to IV and solutions, boosting production capacity amid postwar healthcare expansion. The 1952 acquisition of Hyland Laboratories positioned Baxter as the first U.S. firm to commercially supply human plasma for therapeutic use, including for coagulation disorders. In 1954, leveraging Dutch physician Willem Kolff's design, Baxter developed and marketed the first commercial dialysis system, initiating scalable treatments for acute . By 1960, the company introduced the inaugural solution, expanding options for outpatient renal therapy and demonstrating early commitment to innovative fluid management technologies. These developments, grounded in iterative improvements to sterile processing and material science, established Baxter's foundational role in hospital-based critical care.

Growth and Diversification (1960s–1990s)

During the 1960s, Baxter Laboratories expanded its product lines beyond intravenous solutions into renal care and surgical technologies, introducing the first commercially available solution in 1960, which utilized the patient's peritoneal membrane to filter blood waste. The company listed its shares on the in 1961 and developed the first disposable total bypass oxygenator for open-heart surgery in 1962, reducing infection risks associated with reusable devices. To achieve , Baxter terminated its long-standing distribution agreement with American Hospital Supply in 1963 and established its own sales force while acquiring firms such as Disposable Hospital Products, Dayton Flexible Products, and Cyclo Chemical Corporation to bolster manufacturing capabilities in plastics and chemicals. By 1968, it launched Hemofil, an antihemophilic factor concentrate six times more potent than existing alternatives, diversifying into derivatives for hemophilia treatment. The 1970s marked accelerated revenue growth and innovation in fluid management, with sales reaching $242 million in 1972, earning a position on 500, and surging to $1 billion by 1978 amid consistent 21% annual earnings increases over the prior two decades. Key advancements included the 1970 introduction of Viaflex, the first flexible plastic IV container that eliminated glass breakage and reduced contamination, followed by Mini-Bag premixed drug containers in 1974. In renal therapy, pioneered continuous ambulatory (CAPD) in 1979, enabling home-based treatment and capturing 75% of the global market by the early ; this period also saw acquisitions like American Instrument Company and Surgitool in 1970 for diagnostic and surgical tools, Vicra Sterile Products in 1974, and Clinical Assays in 1976 for technologies. The company rebranded as Travenol Laboratories in 1976 to reflect its merger with Travenol Laboratories, emphasizing diversified transfusion and renal products, while home dialysis sales grew 40% from 1978 levels by 1982. The 1980s focused on large-scale acquisitions to diversify into distribution and diagnostics, culminating in the 1985 purchase of American Hospital Supply Corporation for $1.1 billion (at $51 per share), which integrated and renamed the entity Baxter International Inc. in 1986. This move expanded Baxter's footprint in hospital products and alternative-site care, with further growth via a 1983 partnership with for diagnostics and the 1987 acquisition of Caremark Inc., doubling its outpatient services. International operations, initiated in the late 1950s, grew through European subsidiaries, supporting sales that approached $9 billion by the early 1990s. In the 1990s, Baxter refined its portfolio amid restructuring, launching the needleless Interlink IV Access System in 1991 to enhance safety, the Homechoice automated machine in 1994, and acquiring Ohmeda's Pharmaceutical Products Division in 1998 to enter inhaled anesthetics. Despite challenges like plant closures and workforce reductions in 1990, the company spun off Caremark in 1992 following regulatory scrutiny and reported net sales exceeding $8 billion by 1991, reflecting sustained diversification into , sealants, and global manufacturing, such as a facility for dialysis solutions in 1994.

Modern Era and Strategic Shifts (2000–Present)

In the early , Baxter International pursued diversification through spin-offs and targeted acquisitions to sharpen its focus on core medical technologies. In 2000, the company spun off its cardiovascular and critical care monitoring businesses into Corporation, valued initially at nearly $1 billion, allowing Baxter to concentrate resources on renal care, IV therapies, and bio-pharmaceuticals. Subsequent product innovations included the 2005 launch of V-Link, an IV connector, and FDA clearance for Artiss fibrin in 2007, bolstering its infection prevention and surgical portfolios. The 2010s marked aggressive expansion in renal and infusion technologies via acquisitions, enhancing Baxter's global leadership in dialysis and . In 2011, Baxter acquired Baxa Corporation for pharmacy automation capabilities; in 2012, it purchased Sigma International for smart pumps and Synovis for microsurgery tools. The pivotal 2013 acquisition of AB for approximately $4 billion integrated advanced dialysis products, expanding Baxter's renal therapies market share. By 2015, Baxter spun off its BioScience unit into Baxalta, which was later acquired by (now part of ), streamlining operations away from plasma-derived biologics toward device-centric growth. Further deals included Injectables in 2017 for generics, Recothrom and Preveleak in 2018 for hemostats, Cheetah Medical in 2019 for fluid management, and Seprafilm in 2020 for adhesion barriers. The 2020s brought transformative scale through Baxter's acquisition of Hillrom, announced on September 2, 2021, and completed on December 13, 2021. The deal involved Baxter acquiring Hillrom for $10.5 billion in equity value ($156 per share in cash), representing a 26% premium to Hillrom's closing stock price on July 27, 2021 (the last trading day prior to media reports speculating about a potential transaction), with an enterprise value of approximately $12.5 billion (including assumed debt). This created a ~$15 billion global medtech leader with expanded patient monitoring and respiratory offerings, though it saddled with significant debt. Strategic responses included 2023 announcements of operational enhancements, innovation acceleration, and the planned separation of its kidney care segment—initially branded Vantive—culminating in a $3.8 billion sale to in August 2024, completed by February 2025, to reduce net debt and refocus on medical products, therapies, acute interventions, and surgical equipment segments. This divestiture addressed post-Hillrom leverage challenges, targeting 4-5% organic revenue growth and 16.5% adjusted operating margins by 2025 through simplification and portfolio optimization. Leadership transitions underscored these shifts amid integration hurdles and quality issues. José E. Almeida served as CEO from 2016 until his abrupt retirement in February 2025, after which Brent Shafer assumed interim CEO duties; Andrew Hider was appointed CEO effective September 2025, bringing external expertise from ATS Corporation to drive turnaround efforts. Multiple product recalls, including Life2000 ventilators in 2024 due to charging defects and sodium lots for particulate contamination, highlighted and manufacturing strains, prompting urgent FDA notifications and operational reviews.

Business Operations

Product Portfolio and Segments

Baxter International operates through three primary business segments: Medical Products and Therapies (MPT), Pharmaceuticals, and Healthcare Systems and Technologies (HST). Following the divestiture of its Care business—rebranded as Vantive and sold to Carlyle for approximately $3.8 billion, with the transaction closing on January 31, 2025—the company's focus has shifted to these core areas, emphasizing acute and chronic care solutions, sterile injectables, and connected care technologies. In 2024, sales from continuing operations totaled $10.64 billion, reflecting a 3% increase year-over-year on both reported and constant currency bases. The MPT segment encompasses products for , , and advanced surgery. Key offerings include the Novum IQ system for safe medication delivery, solutions such as Triomel for balanced nutrient provision in critically ill patients, and surgical hemostats like Floseal for controlling during procedures. This segment supports hospital-based care by minimizing risks and enhancing efficiency in fluid management and perioperative settings. In the fourth quarter of 2024, MPT sales were flat on a reported basis but showed low single-digit growth at constant currency. Pharmaceuticals focuses on generic and specialty injectable drugs, including ready-to-use IV formulations, vials, and drug compounding solutions. Notable products comprise anesthesia injectables and premixed medications designed to reduce preparation errors in pharmacies. This segment addresses hospital pharmacy needs with sterile, high-volume generics, experiencing high single-digit sales growth in the fourth quarter of 2024 on both reported and constant currency bases. Healthcare Systems and Technologies provides patient monitoring, support systems, and digital connectivity solutions. Core products include Fluid Management Monitoring System for hemodynamic assessment and integrated care platforms that enable data-driven decisions in intensive care units. This segment faced low single-digit sales declines in the fourth quarter of but contributes to Baxter's emphasis on technology-enabled care transitions. Overall, these segments generated the entirety of Baxter's continuing operations , with expectations for 6-7% reported sales growth in 2025.

Manufacturing and Supply Chain

Baxter International maintains a global network of manufacturing facilities focused on producing pharmaceuticals, medical devices, and renal care products, with nine sites worldwide designed for processes including long-term storage of unstable compounds. In the United States, the company operates multiple sites, including six dedicated to intravenous (IV) fluids, which account for 95% of its U.S. IV fluid production, emphasizing North American sourcing for resilience. Key U.S. facilities include in , and , alongside distribution centers supported by over $2.5 billion in investments across U.S. manufacturing and logistics over the past decade. Internationally, operations span sites in Ireland, , , , and , such as the plant established in 1971 for diversified production. The company's encompasses through end-user delivery, with strategies evolved post-COVID-19 to enhance nimbleness, including supplier diversification and production boosts amid global disruptions like employee absenteeism and material shortages. Baxter prioritizes responsible , extending oversight to upstream producers, and has pursued resilience measures, earning a Resiliency Badge in October 2025 from the Health Industry Resilience Consortium for its IV solutions, solutions, and premix drugs, recognizing preparedness for disruptions. However, vulnerabilities persist; Hurricane Helene in 2024 devastated the Marion, North Carolina, facility, halting IV solution production and prompting nationwide hospital conservation efforts, as this site contributed significantly to U.S. supply. In response to the hurricane, ramped up production at other North American sites and alternative suppliers, reporting progress by October 2024 while acknowledging ongoing constraints into 2025, which contributed to a lowered full-year profit forecast in August 2025 after second-quarter sales of $2.81 billion rose 4% reported but only 1% operationally. These events underscore interdependencies, with 's seven North American and 13 global sites providing some redundancy but highlighting risks from concentrated production, such as in IV fluids. The firm continues investing in multi-site capabilities and to mitigate future shocks, aligning with broader healthcare sector trends toward regionalized .

Corporate Governance

Leadership and Executive Structure

Baxter International's executive leadership is headed by President and Andrew Hider, who assumed the role on September 3, 2025, following an announcement on July 7, 2025. Hider, with over 25 years in medtech, previously served as CEO of ATS Corporation since 2017, bringing expertise in manufacturing and automation to guide Baxter's operations in kidney care, cardiovascular interventions, and other segments. The non-executive Chairman of the Board is Brent Shafer, appointed in August 2025 after serving as lead independent director since joining the board in May 2022; Shafer's background includes executive roles in healthcare technology, emphasizing governance and strategic oversight. Key supporting executives include:
  • Heather Knight, Executive Vice President and Chief Operating Officer since February 2025, overseeing global operations and supply chain following José E. Almeida's retirement as CEO on February 3, 2025, after a tenure from January 2016 that featured restructuring and product focus shifts.
  • Joel Grade, Executive Vice President and Chief Financial Officer since 2023, with prior 25-year experience at Sysco in finance and operations.
  • Charles R. Patel, Executive Vice President and Chief Technology and Innovation Officer, focusing on scientific and technological advancements.
  • Other senior leaders such as James Borzi (general counsel), Stacey Eisen, Gerard Greco (R&D), Tobi Karchmer (medical affairs), Alok Sonig, and Anita Zielinski (comptroller), who collectively manage legal, commercial, and administrative functions reporting to the CEO.
The Board of Directors provides strategic direction and risk oversight, comprising Hider as a director alongside independents including Stephen H. Rusckowski (compensation committee involvement), William A. Ampofo II, Jeffrey A. Craig, Patricia B. Morrison, and Stephen N. Oesterle, M.D., with Shafer as chair; the board maintains committees for audit, compensation, and governance to ensure accountability in Baxter's global medtech operations. This structure supports Baxter's focus on innovation and efficiency amid competitive healthcare pressures, with recent transitions aimed at and operational stability.

Ownership and Shareholder Relations

Baxter International Inc. is a publicly traded company on the under the BAX, with its shares widely held by institutional investors. As of March 2025, institutional accounted for approximately 96.21% of outstanding shares, reflecting strong dominance by large asset managers and funds. Insider remains minimal at around 0.46%, indicating limited direct control by company executives and directors. The largest shareholders include , Inc., holding 13.2% (approximately 67.7 million shares), , Inc. with 12.1% (62.2 million shares), and Pzena Investment Management, Inc. at 10.8% (55.5 million shares), followed by and other value-oriented investors. These institutions primarily engage through passive indexing and strategies, with periodic adjustments reported via SEC 13F filings. Retail investor participation is negligible, comprising less than 1% of total . Baxter maintains active shareholder relations through its investor relations team, which facilitates communication via quarterly earnings conference calls, annual shareholder meetings, and SEC filings. The company emphasizes transparent governance, with its board overseeing proxy voting and engagement protocols as outlined in its corporate governance guidelines updated February 3, 2025. In October 2025, shareholders faced a class action lawsuit alleging securities fraud related to undisclosed operational issues, with a lead plaintiff deadline of December 15, 2025, potentially impacting investor confidence and relations. No significant activist campaigns have been reported in recent filings, though institutional holders monitor performance closely amid the company's strategic shifts.

Innovations and Contributions

Key Technological Advancements

Baxter International pioneered the commercialization of intravenous (IV) solutions in 1931 through the Don Baxter Intravenous Products Company, enabling standardized fluid and medication delivery to patients and reducing risks associated with improvised preparations. This innovation laid the foundation for modern hospital-based hydration and drug administration practices. In 1939, the company introduced the Transfuso-Vac blood collection system, which allowed blood to be stored for up to 21 days under vacuum conditions, facilitating the establishment of blood banks and transforming by enabling scalable blood preservation. By 1941, Baxter advanced plasma processing with the Plasma-Vac container, permitting the separation and storage of plasma from , which supported wartime medical efforts and expanded component therapy options. In renal care, Baxter collaborated with physician Willem Kolff to commercialize the first dialysis system in 1956, marking a breakthrough in treating acute and chronic by filtering extracorporeally using semipermeable membranes. This technology evolved into home-based solutions, including the 1979 introduction of continuous ambulatory (CAPD), which utilized the patient's peritoneal membrane as a natural filter and allowed self-administered treatments without machinery, improving accessibility for end-stage renal disease patients. Surgical innovations included the 1962 development of the first disposable total bypass , which oxygenated blood during open-heart procedures, reducing infection risks from reusable equipment and enabling safer operations. In , Baxter's 1968 launch of Hemofil, an antihemophilic factor concentrate six times more potent than prior formulations, enhanced clotting treatments for hemophilia patients by providing a stable, virus-inactivated plasma-derived product. These advancements, grounded in iterative of disposable plastics and biological processing, underscore Baxter's role in shifting healthcare from rudimentary to scalable, patient-centric technologies.

Impact on Healthcare Delivery

Baxter's innovations in renal care, particularly through the Sharesource remote patient management platform integrated with automated (APD) systems, have extended patient time on home dialysis . A of nearly 1,500 home PD patients in from 2017 to 2019, followed up in 2021, found that Sharesource users maintained for 18.9 months on average, compared to 15.5 months for non-users, representing a statistically significant increase of 3.4 months. Independent analyses corroborate these findings, showing improved adherence to APD treatments via remote monitoring, especially among patients with prior poor compliance, thereby reducing treatment burden and enhancing patient-centered outcomes like . These advancements facilitate earlier shifts to home-based care, decreasing reliance on in-center dialysis and associated hospitalization risks. In , the Novum IQ large volume , cleared by the U.S. FDA on April 1, 2024, streamlines delivery of fluids and medications across hospital settings by unifying large-volume and syringe pump interfaces, minimizing clinician training needs and programming errors. Integrated Dose IQ safety software employs customizable drug libraries and safeguards, while the IQ Enterprise Connectivity Suite enables bi-directional electronic medical record , auto-programming, and real-time data analytics for continuous quality improvement. This connectivity supports precise, low-rate infusions for vulnerable populations such as neonates and , allowing clinicians to redirect time from device management to direct patient interaction and reducing workflow disruptions in high-acuity environments. Baxter's portfolio, including ready-to-use (PN) formulations with balanced , carbohydrates, , vitamins, and electrolytes, addresses in patients unable to tolerate oral or enteral intake, a condition linked to 23% 30-day readmission rates in the U.S.—over 50% higher than non-malnourished peers. Tailored PN solutions for renal dysfunction optimize support during when supplements prove insufficient, aiding recovery and functional outcomes. Broader connected care platforms aggregate device data to generate actionable insights, informing clinical decisions that enhance efficiency, documentation accuracy, and overall care personalization across , , and home settings.

Philanthropy and Sustainability

Charitable Initiatives

The Baxter International Foundation, established in 1982 as the company's philanthropic arm, directs grants toward access to healthcare for underserved populations, K-12 STEM education to develop future healthcare innovators, and community resilience initiatives. The foundation supports strategic partnerships rather than unsolicited requests, emphasizing long-term impact through global collaborations. In healthcare access, Baxter has committed over $2 million since 2019 to care centers in , enabling safe surgical procedures for children with cleft conditions and expanding service availability in underserved regions. Partnerships with , including $1.5 million for response efforts starting in 2020, have funded programs, water and sanitation improvements, and nutrition projects in countries like and . Through the Transformative Innovation Awards with , the foundation granted $115,000 each to multiple community health centers in 2023 for nutrition-integrated care models, contributing over $1 million total to 12 such organizations since the program's inception. For community resilience, Baxter and its foundation have donated more than $9 million to the since 1986, supporting disaster preparedness, response, and recovery programs worldwide. Product donations, including medical supplies for crises such as Australian bushfires, earthquakes, and the , bridge immediate gaps in rural , , and other affected areas. In , the foundation allocated $3 million in grants to relief organizations, bringing cumulative commitments in that effort to over $13.5 million. Baxter's overall charitable giving reached $38.18 million in 2021, encompassing cash grants, product donations, and employee-driven programs. The company matches employee donations and encourages volunteerism, such as through annual Days of Service yielding over 500 volunteer hours and $40,000 in contributions in 2021, alongside scholarships for post-high school education for employees' children. Baxter aims to invest $275 million by 2030 in underserved communities via these combined efforts.

Environmental and Social Responsibility Efforts

Baxter International's corporate responsibility framework, outlined in its 2030 Commitment, emphasizes three pillars: empowering patients through quality manufacturing, protecting the planet via , and championing people and communities through workplace safety and . The company publishes annual reports detailing progress, with the 2024 edition highlighting investments in amid its healthcare operations spanning manufacturing and supply chains. On the environmental front, Baxter targets carbon neutrality in direct operations by 2040 and a 25% reduction in Scope 1 and 2 by 2030, using 2020 as the baseline. In 2024, Scope 1 and 2 emissions totaled 501,000 metric tons of CO2 equivalent, reflecting a 13.5% decrease from 2023 and 18.8% from the baseline, supported by 175 projects that cost $12 million and are projected to save 74 gigawatt-hours annually while avoiding 22,000 metric tons of CO2 equivalent emissions. Renewable energy constituted 36% of total usage (964,000 megawatt-hours), with the facility achieving certified carbon neutrality in 2024 following its 2023 milestone. Additional efforts include strategic water management plans at 16 priority sites, where water withdrawal fell 1.7% to 14.7 million cubic meters in 2024, and waste diversion, with 70.5% of 79,700 metric tons of total waste kept from landfills. Sustainable procurement advanced to cover 56% of supplier spend through ethics and compliance commitments, alongside supplier audits. Social responsibility initiatives prioritize employee safety, achieving a total recordable incident rate of 0.38 in 2024, placing it in the top for industry benchmarks. Community support reached $38.21 million in investments, including $15.63 million in product donations to aid organizations across 74 countries and $13.7 million from the Baxter Foundation, contributing toward a $275 million cumulative goal by 2030. Partnerships, such as a $7 million collaboration from 2020 to 2024, focused on underserved areas, while employee programs logged 12,300 volunteer hours and 4.91 million training hours, yielding an engagement score of 78%. These efforts align with broader aims to enhance access to healthcare in disaster-affected and low-resource settings through product donations and strategic alliances.

Acquisitions, Divestitures, and Restructuring

Major Deals and Integrations

Baxter International's acquisition of American Hospital Supply Corporation in , valued at approximately $3.8 billion through a combination of cash and securities at $51 per share, marked a pivotal expansion in healthcare distribution and hospital supply capabilities. Initially a hostile bid, the deal integrated American Hospital Supply's and product lines with 's manufacturing strengths, forming a combined entity with enhanced market reach and operational scale in the hospital sector. Subsequent deals bolstered specialized portfolios, such as the 1998 purchase of Ohmeda's Pharmaceutical Products Division, which established Baxter's leadership in inhaled anesthetics through seamless incorporation of production and distribution assets. In 2013, the acquisition of AB, a global renal care provider, added advanced dialysis technologies and expanded Baxter's offerings, with integration focusing on harmonizing R&D and manufacturing to accelerate product innovation. The 2021 acquisition of , announced on September 2, 2021, for $10.5 billion in equity value ($156 per share in cash, representing a 26% premium to Hillrom's closing stock price on July 27, 2021, the last trading day before media speculation), was completed on December 13, 2021. It represented Baxter's largest deal, with an enterprise value of approximately $12.5 billion including debt, aimed at combining connected care solutions to improve patient outcomes and global access. Integration efforts emphasized cultural and talent alignment amid disruptions, including virtual talent reviews of Hillrom's vice presidents, frequent managerial communications, and a hybrid work model requiring 2-3 office days weekly to foster community and productivity. These strategies targeted $250 million in annual pre-tax cost synergies by year three, high single-digit return on invested capital by year five, and low double-digit accretion starting in year one.

Recent Spin-offs and Asset Sales

In May 2023, Baxter International signed a definitive agreement to divest its BioPharma Solutions business, which provided contract development and manufacturing services for biologics and pharmaceuticals, to firms and for $4.25 billion in cash. The transaction, yielding net proceeds of approximately $3.4 billion after taxes, closed on October 2, 2023, with the acquired unit rebranded as Simtra BioPharma Solutions; this divestiture aimed to streamline Baxter's operations and reduce debt incurred from prior acquisitions. Baxter initially announced plans in late 2023 to spin off its Care and Acute Therapies segment—encompassing , , and treatments generating about $4.5 billion in annual revenue—as a standalone named Vantive, with the separation targeted for mid-2024 to unlock and focus on core medical products. However, amid market volatility and strategic priorities to deleverage its , Baxter pivoted to a sale, signing a definitive agreement on August 13, 2024, to divest the segment (retained as Vantive) to for $3.8 billion. The deal closed on January 31, 2025, enabling Vantive to operate independently as a vital organ therapy provider while providing Baxter with proceeds to pay down approximately $15 billion in net debt from earlier expansions. These transactions, part of Baxter's broader post-2021 Hillrom acquisition, contributed to projected sales growth of 5-6% from continuing operations in 2025 by shedding non-core assets and enhancing financial flexibility, though they prompted a 58.6% cut to $0.68 annually to preserve capital. Smaller product line divestitures were under consideration as of early 2025 to further refine the portfolio, but no major additional deals were finalized by mid-year.

Controversies and Regulatory Challenges

Product Safety Incidents and Recalls

In 2008, Baxter International faced a major crisis involving contaminated sodium injection multidose vials sourced from a Chinese supplier, which contained oversulfated as an , leading to severe allergic reactions including , , and gastrointestinal symptoms. The U.S. (FDA) reported 81 deaths and over 800 adverse events associated with the product by mid-2008, prompting Baxter to initiate a recall of nine initial lots on January 17, followed by broader recalls affecting 72 medical devices and drug products from multiple manufacturers. Investigations revealed the contaminant evaded standard purity tests by mimicking 's activity, highlighting vulnerabilities in active pharmaceutical ingredients. Subsequent recalls have involved infusion and dialysis equipment. In March 2024, the FDA classified Baxter's recall of ExactaMix Pro 1200 and Pro 2400 compounding devices as Class I—the most serious category—due to software errors causing incorrect ingredient dosing, with potential for serious injury or death; over 20,000 units were affected worldwide. For dialysis products, Baxter issued a correction in November 2024 for AK 98 hemodialysis machines, also designated Class I by the FDA, after detecting elevated levels of toxic NDL-PCBAs (non-dioxin-like polychlorinated biphenyls) in new units with under 500 hours of runtime, risking patient exposure during treatment. Earlier, in 2022, recalls of Clearlink solution sets and MiniCap Extended Life peritoneal dialysis transfer sets addressed risks of leaks exposing patients to air, particulates, or chemical damage from incompatible cleaners, classified as Class I due to infection or peritonitis hazards. Infusion-related issues persisted into 2025, with Baxter's Spectrum IQ infusion pumps subject to an FDA early alert for motor movement errors (codes 20602/20603) that could halt therapy, reporting 79 serious injuries and two deaths as of June 27. Intravenous solutions have seen multiple voluntary recalls, including lots in 2015 and 2024 for particulate matter, endotoxins, or elevated in products like Extraneal, potentially causing , fever, or organ damage if infused. These incidents underscore recurring challenges in sterile and device software, often tied to FDA Class I designations indicating high risk of adverse health consequences.

Pricing and Market Practices Scrutiny

In 2009, International faced multidistrict antitrust litigation alleging that it, along with competitors including and the Plasma Protein Therapeutics Association, engaged in a from 2004 to 2008 to restrict output and fix prices of plasma-derivative protein therapies such as intravenous immunoglobulin (IVIG) and , which are critical for treating immune deficiencies and burns. Plaintiffs, including hospitals and direct purchasers, claimed the firms coordinated through trade associations to allocate market shares and limit production capacity, leading to price increases of up to 400% for IVIG between 2004 and 2007. denied the allegations, asserting independent decisions driven by shortages and regulatory constraints rather than . The case culminated in a $64 million settlement by in April 2014 with a class of purchasers, approved by the U.S. District Court for the Northern District of , without admission of liability; this represented a portion of broader settlements totaling over $128 million across defendants. Independent analyses noted that while plasma supply constraints were real—due to factors like U.S. donor eligibility rules and global capacity limits—the timing of parallel production cuts raised competitive concerns, though courts dismissed some claims for lack of of agreement. Separately, during the 2017-2018 U.S. of intravenous (IV) saline solutions, the Department of Justice's Antitrust Division investigated potential communications among producers, including , which held a dominant market position supplying over 50% of U.S. IV fluids. The probe, initiated amid reports of supply disruptions from manufacturing issues and hurricanes, examined whether firms shared sensitive pricing or capacity data in ways that could facilitate coordination. disclosed the inquiry in 2018 filings and cooperated fully; the DOJ closed the investigation in February 2019 without charges or findings of violation, citing insufficient evidence of anticompetitive conduct. A related proposed class action lawsuit accused and Pfizer's unit of conspiring to fix IV solution prices during the shortage, but it did not advance to a merits ruling, reflecting challenges in proving intent amid verifiable exogenous shocks like plant closures. In October 2024, Hurricane Helene damaged 's North Cove, facility—producing about 60% of U.S. IV fluids—prompting federal warnings against price gouging by distributors and secondary sellers, though no enforcement actions targeted itself, which instead collaborated with regulators on allocation and imports. These episodes underscore broader market vulnerabilities in concentrated segments like IV fluids and plasma products, where single-supplier disruptions amplify pricing pressures without necessarily implying firm misconduct.

Financial Performance and Market Position

Baxter International's reported revenues have grown substantially since the late , driven by expansions in manufacturing, renal care, and pharmaceutical services, though trends have been markedly shaped by major corporate restructurings. In 2000, annual stood at approximately $6.5 billion, increasing to around $9.7 billion by 2005 and $12.3 billion by 2010 amid and smaller acquisitions in therapies and critical care products. By 2014, revenues peaked at $16.7 billion, bolstered by operations including plasma-based therapies. The 2015 spin-off of Baxalta, encompassing the biopharmaceutical unit with roughly $6 billion in annual sales, refocused Baxter on medical products and sharply reduced its revenue base to about $10 billion that year. Subsequent growth was modest, reaching $11.7 billion in 2020 through advancements in kidney care and surgical equipment. The December 2021 acquisition of Hillrom for $12.4 billion added patient monitoring and diagnostics capabilities, elevating total revenues to approximately $12.8 billion in 2021 (on a basis including partial-year Hillrom contribution). Post-2021, divestitures reversed some gains: the 2023 sale of BioPharma Solutions (generating over $2 billion annually) and the 2024 spin-off of the Kidney Care segment as Vantive (with $3.7 billion in 2022 renal sales) shifted emphasis to core medtech, contracting continuing operations . Full-year continuing operations sales totaled $10.64 billion in 2024, up 3% from 2023's $10.36 billion, reflecting operational resilience amid restructuring but below pre-divestiture levels.
YearTotal Revenue (USD billions)Year-over-Year Change (%)Key Event Impact
201416.7+5Pre-Baxalta spin-off peak
2015~10.0-40Baxalta spin-off
202011.7+3 in core segments
202112.1+4Hillrom acquisition boost
202210.1-17Integration and early divest prep
202310.4+3BioPharma sale (discontinued ops)
202410.6+3Vantive spin-off; continuing ops

Recent Results and Projections (2020s)

Baxter International's revenue from continuing operations grew modestly in the early amid restructuring efforts, including the 2024 spin-off of its Kidney Care segment into Vantive, which separated renal products and services as a standalone entity effective October 1, 2024. For full-year 2023, revenue reached $10.36 billion, reflecting a 3.01% increase from 2022 levels, while 2024 revenue climbed to $10.636 billion, up 2.66% year-over-year, driven by core medtech segments like surgical and acute therapies but offset by divestitures. Net income attributable to Baxter swung to a $649 million loss in 2024 on a basis, or ($1.27) per diluted share, compared to a $2.656 billion profit in 2023; the prior year's gain included one-time benefits from the Vantive preparation and other adjustments. In 2025, first-quarter results showed growth aligning with updated guidance, prompting Baxter to initially project full-year sales from continuing operations at 7-8% on a reported basis (4-5% operational), though this was revised downward after the second quarter to 6-7% reported (3-4% operational) due to headwinds and segment-specific pressures. Third-quarter 2025 earnings, scheduled for release on October 30, 2025, are anticipated to reflect continued operational challenges, with analysts estimating quarterly around $2.88 billion and EPS of $0.30. Looking ahead, analyst consensus for 2025-2026 projects moderate revenue expansion, with Marketscreener forecasting rising to approximately $1.102 billion in 2025 and $1.284 billion in 2026, supported by cost efficiencies post-spin-off and growth in connected care technologies. Baxter's stock price has declined sharply in the , falling about 36.88% over the trailing 52 weeks as of late 2025, underperforming broader market indices amid profitability volatility and separation-related disruptions. maintains a "Hold" rating with an average price target of $30.78, implying potential upside from the October 2025 close near $23, though forecasts vary widely from $19 to $47.
YearRevenue ($B, continuing ops)Net Income ($M, GAAP)
202310.362,656
202410.636-649
2025 (proj.)~11.0-11.4 (implied from guidance)~1,100
Note: 2025 revenue projection derived from 6-7% growth on 2024 base; earlier 2020-2022 figures exclude discontinued operations for comparability.

References

  1. https://www.baxter.com/
  2. https://investor.baxter.com/investors/investor-overview/default.aspx
  3. https://www.baxter.com/our-story/our-history
  4. https://mea.baxter.com/en/our-story/our-history
  5. https://www.baxter.com/our-story
  6. https://www.baxter.com/perspectives/people-baxter
  7. https://www.justice.gov/archives/opa/pr/baxter-healthcare-corporation-pay-more-18-million-resolve-criminal-and-civil-liability
  8. https://www.morningstar.com/news/business-wire/20251020382050/baxter-international-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-bax
  9. https://www.cbs42.com/business/press-releases/accesswire/1090294/bax-lawsuit-baxter-international-inc-sued-for-securities-fraud-after-stock-plummets-22-contact-bfa-law-if-you-suffered-losses
  10. https://www.baxter.com/baxter-newsroom/baxter-reports-second-quarter-2025-results
  11. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2025/Baxter-Reports-Second-Quarter-2025-Results/default.aspx
  12. https://findingaids.library.northwestern.edu/agents/corporate_entities/1573
  13. http://www.encyclopedia.chicagohistory.org/pages/2564.html
  14. https://dcfmodeling.com/blogs/history/bax-history-mission-ownership
  15. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2025/Baxter-Reports-Fourth-Quarter-and-Full-Year-2024-Results/default.aspx
  16. https://www.baxter.com/baxter-newsroom/baxter-reports-fourth-quarter-and-full-year-2024-results
  17. http://www.encyclopedia.chicagohistory.org/pages/806.html
  18. https://www.encyclopedia.com/books/politics-and-business-magazines/baxter-international
  19. https://www.fundinguniverse.com/company-histories/baxter-international-inc-history/
  20. https://www.linkedin.com/posts/rezazahiri_%25F0%259D%2590%2581%25F0%259D%2590%259A%25F0%259D%2590%25B1%25F0%259D%2590%25AD%25F0%259D%2590%259E%25F0%259D%2590%25AB-%25F0%259D%2590%2592%25F0%259D%2590%25A9%25F0%259D%2590%25A2%25F0%259D%2590%25A7%25F0%259D%2590%25A8%25F0%259D%2590%259F%25F0%259D%2590%259F%25F0%259D%2590%25AC-%25F0%259D%2590%258E%25F0%259D%2590%25AF%25F0%259D%2590%259E%25F0%259D%2590%25AB-%25F0%259D%2590%25AD-activity-7307443404135612416-r8ls
  21. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2013/Baxter-Completes-Acquisition-of-Gambro-AB-and-Enhances-Global-Leadership-in-Renal-Therapies/default.aspx
  22. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2012/Baxter-Enhances-Renal-Therapies-Portfolio-with-Acquisition-of-Gambro/default.aspx
  23. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2021/Baxter-to-Acquire-Hillrom-Expanding-Connected-Care-and-Medical-Innovation-Globally/default.aspx
  24. https://www.baxter.com/baxter-newsroom/baxter-completes-acquisition-hillrom-creating-15-billion-global-medtech-leader
  25. https://www.baxter.com/baxter-newsroom/baxter-announces-strategic-actions-enhance-operational-effectiveness-accelerate
  26. https://www.baxter.com/baxter-newsroom/baxter-announces-definitive-agreement-divest-its-vantive-kidney-care-segment
  27. https://www.baxter.com/baxter-newsroom/baxter-issues-urgent-medical-device-recall-life2000-ventilator-due-potential
  28. https://www.baxter.com/baxter-newsroom/baxter-issues-voluntary-nationwide-recall-one-lot-heparin-sodium-09-sodium-chloride
  29. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2025/Baxter-Appoints-Andrew-Hider-Chief-Executive-Officer/default.aspx
  30. https://www.reuters.com/markets/companies/BAX.N
  31. https://finance.yahoo.com/quote/BAX/
  32. https://www.bioworld.com/articles/716793-baxter-completes-38b-sale-of-renal-care-biz-shakes-up-c-suite
  33. https://pharmaceuticals.baxter.com/
  34. https://ushospitalproducts.baxter.com/our-products
  35. https://pharmaceuticals.baxter.com/manufacturing-and-distribution
  36. https://ushospitalproducts.baxter.com/specialties/supply-resilience
  37. https://ushospitalproducts.baxter.com/specialties/supply-chain-investments
  38. https://www.globaldata.com/company-profile/baxter-international-inc/locations/
  39. https://www.baxter.com/perspectives/healthcare-insights/supply-chain-innovation-delivers-more-nimble-efficient-solutions
  40. https://ushospitalproducts.baxter.com/sites/g/files/ebysai2186/files/2022-02/Baxter%2520Update%2520on%2520Global%2520Supply%2520Challenges.pdf
  41. https://www.baxter.com/partners-suppliers/baxter-suppliers
  42. https://www.otcmarkets.com/stock/BAX/news/Baxter-is-First-Manufacturer-to-Achieve-Gold-Resiliency-Badge-for-IV-Solutions-Nutrition-Solutions-and-Premix-Drugs-from?e&id=3320282
  43. https://shea-online.org/baxter-iv-supply-chain-disruption-resources/
  44. https://www.fiercehealthcare.com/providers/us-hospitals-prep-supply-chain-constraints-wake-baxter-international-plant-closure
  45. https://www.aha.org/2024-10-24-baxter-provides-updates-efforts-increase-access-and-supply-iv-solutions
  46. https://procurementmag.com/news/baxter-cuts-2025-forecast-after-poor-quarterly-numbers
  47. https://www.baxter.com/our-story/our-leadership/andrew-hider
  48. https://www.baxter.com/our-story/our-leadership/brent-shafer
  49. https://www.baxter.com/our-story/our-leadership/heather-knight
  50. https://www.baxter.com/baxter-newsroom/baxter-announces-ceo-retirement-and-appointment-coo
  51. https://www.baxter.com/our-story/our-leadership/joel-grade
  52. https://www.marketscreener.com/quote/stock/BAXTER-INTERNATIONAL-INC-127525208/company-governance/
  53. https://www.baxter.com/our-story/our-leadership
  54. https://simplywall.st/stocks/us/healthcare/nyse-bax/baxter-international/management
  55. https://www.sec.gov/Archives/edgar/data/10456/000162828025014747/bax-20250325.htm
  56. https://us.trendlyne.com/us/equity/ownership/1402979/BAX/mar-2025/baxter-international-inc/
  57. https://www.tipranks.com/stocks/bax/ownership
  58. https://simplywall.st/stocks/us/healthcare/nyse-bax/baxter-international/ownership
  59. https://www.wallstreetzen.com/stocks/us/nyse/bax/ownership
  60. https://investor.baxter.com/investors/resources-and-faqs/default.aspx
  61. https://www.baxter.com/our-story/our-governance
  62. https://natlawreview.com/press-releases/important-notice-long-term-shareholders-baxter-international-inc-nyse-bax
  63. https://fintel.io/so/us/bax
  64. https://www.baxter.com/baxter-newsroom/baxter-presents-data-indicating-sharesource-increases-patients-time-home-dialysis
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC10088459/
  66. https://link.springer.com/article/10.1007/s11255-022-03178-5
  67. https://www.baxter.com/baxter-newsroom/baxter-announces-us-fda-clearance-novum-iq-large-volume-infusion-pump-and-dose-iq
  68. https://www.baxter.com/healthcare-professionals/nutritional-care
  69. https://emeaclinicalnutrition.baxter.com/therapies/nephrology
  70. https://www.baxter.com/perspectives/healthcare-insights/conversation-about-baxters-role-healthcare-connectivity
  71. https://fconline.foundationcenter.org/fdo-grantmaker-profile?key=AMER039
  72. https://www.baxter.com/our-story/corporate-responsibility/championing-our-people-and-communities-0
  73. https://www.baxter.com/baxter-newsroom/baxter-international-foundation-commits-2-million-operation-smile-care-centers
  74. https://www.unicefusa.org/about-unicef-usa/partnerships/companies/baxter
  75. https://www.directrelief.org/2023/10/direct-relief-baxter-international-foundation-announce-2023-transformative-innovation-awards-in-community-health/
  76. https://www.redcross.org/donations/companies-and-foundations/giving-opportunities-and-corporate-supporters/baxter-international-foundation.html
  77. https://www.baxter.com/inside-look-how-baxter-gives-back
  78. https://www.baxter.com/baxter-newsroom/baxter-international-foundation-announces-3-million-new-grants-organizations
  79. https://www.baxter.com/sites/g/files/ebysai3896/files/2022-06/Baxter_2021_Corporate_Responsibility_Report.pdf
  80. https://www.baxter.com/giving-back-our-day-service
  81. https://www.baxter.com/our-story/corporate-responsibility-0
  82. https://www.baxter.com/sites/g/files/ebysai3896/files/2025-06/2024_Baxter_Corporate_Responsibility_Report.pdf
  83. https://www.baxter.com/our-story/corporate-responsibility/protecting-our-planet-0
  84. https://www.latimes.com/archives/la-xpm-1985-07-16-fi-7049-story.html
  85. https://www.nytimes.com/1985/07/16/business/baxter-s-merger-bid-accepted.html
  86. https://www.spencerstuart.com/research-and-insight/managing-a-merger-integration-a-conversation-with-baxter-chro-jeanne-mason
  87. https://www.baxter.com/baxter-newsroom/baxter-signs-definitive-agreement-divest-its-biopharma-solutions-business-advent
  88. https://www.businesswire.com/news/home/20231001831374/en/Advent-International-and-Warburg-Pincus-Complete-Acquisition-of-Baxters-BioPharma-Solutions-Business
  89. https://www.forbes.com/sites/joecornell/2024/02/15/baxter-to-spin-off-vantive-kidney-care-unit-in-july-2024/
  90. https://www.tsinetwork.ca/daily-advice/growth-stocks/baxter-projects-5-6-sales-growth-following-strategic-divestitures
  91. https://www.chicagobusiness.com/health-care/small-divestitures-acquisitions-ahead-baxter-international
  92. https://www.nejm.org/doi/full/10.1056/NEJMoa0803200
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC2249657/
  94. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/baxter-healthcare-recalls-exactamix-pro-1200-and-pro-2400-due-software-error
  95. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/hemodialysis-correction-baxter-issues-correction-ak-98-hemodialysis-machines-due-risk-patient
  96. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-infusion-pump-issue-baxter
  97. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-initiates-voluntary-recall-two-lots-iv-solutions-due-potential-presence-particulate-matter
  98. https://www.cohenmilstein.com/case-study/plasma-derivative-protein-therapies-blood-plasma/
  99. https://www.jonesday.com/en/practices/experience/2010/06/baxter-international-defends-against-multidistrict-antitrust-class-actions-involving-plasma-derived-biological-products
  100. https://www.courthousenews.com/class-loses-ground-in-plasma-antitrust-case/
  101. https://appliedantitrust.com/04_private_actions/standing/plasma_ndill1_9_2012.pdf
  102. https://chicago.suntimes.com/news/2014/4/21/18594044/baxter-settles-pricing-lawsuit-for-64-million
  103. https://www.law360.com/lifesciences/articles/530125/judge-oks-64m-baxter-plasma-products-antitrust-deal
  104. https://www.pymnts.com/cpi-posts/us-baxter-puts-price-fixing-woes-behind-with-64m-settlement/
  105. https://www.reuters.com/article/u-s-closes-iv-solution-shortage-antitrust-probe-baxter-says-idUSKCN1QB25K/
  106. https://www.bloomberg.com/news/newsletters/2024-11-05/supply-chain-latest-iv-fluid-shortages-at-hospitals-in-the-us
  107. https://www.fiercehealthcare.com/providers/widespread-iv-fluid-shortages-have-providers-starting-cancel-procedures-survey-finds
  108. https://companiesmarketcap.com/baxter/revenue/
  109. https://www.annualreports.com/HostedData/AnnualReportArchive/b/NYSE_BAX_2014.pdf
  110. https://www.baxter.com/baxter-newsroom/baxter-reports-fourth-quarter-and-full-year-2020-results
  111. https://www.sec.gov/Archives/edgar/data/10456/000162828022010923/bax-20220428xex991.htm
  112. https://www.statista.com/statistics/241512/revenues-of-baxter-international-by-division/
  113. https://www.macrotrends.net/stocks/charts/BAX/baxter/revenue
  114. https://www.macrotrends.net/stocks/charts/BAX/baxter/net-income
  115. https://investor.baxter.com/investors/events-and-news/news/press-release-details/2025/Baxter-Reports-First-Quarter-2025-Results/default.aspx
  116. https://www.moomoo.com/stock/BAX-US/earnings
  117. https://www.marketscreener.com/quote/stock/BAXTER-INTERNATIONAL-INC-11763/finances/
  118. https://stockanalysis.com/stocks/bax/statistics/
  119. https://stockanalysis.com/stocks/bax/forecast/
Add your contribution
Related Hubs
User Avatar
No comments yet.